These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1079 related items for PubMed ID: 35392977

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
    Yang M, Lu J, Zhang G, Wang Y, He M, Xu Q, Xu C, Liu H.
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
    [Abstract] [Full Text] [Related]

  • 3. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L.
    J Exp Clin Cancer Res; 2020 Sep 07; 39(1):180. PubMed ID: 32892748
    [Abstract] [Full Text] [Related]

  • 4. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, Zhang W, Sun J, Cao C.
    J Immunother Cancer; 2020 May 07; 8(1):. PubMed ID: 32461345
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. TGF-β1-Induced SOX18 Elevation Promotes Hepatocellular Carcinoma Progression and Metastasis Through Transcriptionally Upregulating PD-L1 and CXCL12.
    Chen J, Feng W, Sun M, Huang W, Wang G, Chen X, Yin Y, Chen X, Zhang B, Nie Y, Fan D, Wu K, Xia L.
    Gastroenterology; 2024 Jul 07; 167(2):264-280. PubMed ID: 38417530
    [Abstract] [Full Text] [Related]

  • 8. ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC.
    Luo B, Liu X, Zhang Q, Liang G, Zhuang Y.
    Int Immunopharmacol; 2024 Oct 25; 140():112875. PubMed ID: 39116492
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, Huang M, Vlad AM, Lu B, Oesterreich S, Davidson NE, Huang Y.
    Oncogene; 2019 Jan 25; 38(3):390-405. PubMed ID: 30111819
    [Abstract] [Full Text] [Related]

  • 13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM, Khan PP, Wang H, Tsai WB, Qiao Y, Yu B, Larrick JW, Hu MC.
    J Immunother Cancer; 2021 Dec 25; 9(12):. PubMed ID: 34887262
    [Abstract] [Full Text] [Related]

  • 14. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma.
    Iwagami Y, Casulli S, Nagaoka K, Kim M, Carlson RI, Ogawa K, Lebowitz MS, Fuller S, Biswas B, Stewart S, Dong X, Ghanbari H, Wands JR.
    Heliyon; 2017 Sep 25; 3(9):e00407. PubMed ID: 28971150
    [Abstract] [Full Text] [Related]

  • 15. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX.
    Gut; 2019 Sep 25; 68(9):1653-1666. PubMed ID: 30902885
    [Abstract] [Full Text] [Related]

  • 16. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma.
    Song F, Hu B, Liang XL, Cheng JW, Wang CG, Wang PX, Wang TL, Tang PJ, Sun HX, Guo W, Zhou J, Fan J, Chen Z, Yang XR.
    Clin Transl Med; 2024 Aug 25; 14(8):e1738. PubMed ID: 39095323
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M, Li J, Wu S, Wu C, Yu Y, Liu Y.
    Cancer Med; 2023 Feb 25; 12(3):2906-2917. PubMed ID: 36073303
    [Abstract] [Full Text] [Related]

  • 18. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
    Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR.
    Vaccine; 2015 Mar 03; 33(10):1256-66. PubMed ID: 25629522
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.